1642
PATENTCase Docket No. LANCELL.002CP1
Date: November 17, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Cowing, Carol O.
Appl. No. : 09/809,158
Filed : March 15, 2001
For : METHOD TO ENHANCE THE
IMMUNOGENICITY OF AN
ANTIGEN
Examiner : Canella, Karen A.
Group Art Unit : 1642

I hereby certify that this correspondence and all
marked attachments are being deposited with the
United States Postal Service as first class mail in
an envelope addressed to: Commissioner for
Patents, Mail Stop Amendment, P.O. Box 1450,
Alexandria, VA 22313-1450, on

November 17, 2004

(Date)

Marina L. Gordey, Reg. No. 52,950


TRANSMITTAL LETTER

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with eight (8) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Marina L. Gordey
Registration No. 52,950
Agent of Record
Customer No. 20,995
(805) 547-5580

**INFORMATION DISCLOSURE STATEMENT**

Applicant	:	Cowing, Carol O.
App. No.	:	09/809,158
Filed	:	March 15, 2001
For	:	METHOD TO ENHANCE THE IMMUNOGENICITY OF AN ANTIGEN
Examiner	:	Canella, Karen A.
Group Art Unit	:	1642

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing 8 references that are also enclosed.

This Information Disclosure Statement is being filed before the mailing date of a final action under 37 C.F.R. § 1.113 and before the mailing date of a Notice of Allowance under § 1.311. A certification under 37 C.F.R. § 1.97(e) is set forth below. Thus, no fee is required as set forth in 37 C.F.R. § 1.97(c).

CERTIFICATION UNDER 37 C.F.R. § 1.97(e)(2)

I hereby certify that no item of information contained in this Statement was cited in a communication from a foreign Patent Office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R.

Appl. No. : 09/809,158
Filed : March 15, 2001

Docket No. LANCELL.002CP1
Customer No. 20,995

§ 1.56(c) more than 30 days prior to the filing of this Information Disclosure Statement.



Dated: November 14, 2004


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

By: _____

Marina L. Gordey
Registration No. 52,950
Agent of Record
Customer No. 20,995
(805) 547-5580

O:\DOCS\MXG\MXG-6309.DOC:vr
111104



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
LANCELL.002CP1APPLICATION NO.
09/809,158INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Cowing, Carol O.FILING DATE
March 15, 2001GROUP
1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	4,353,896	10/12/1982	Levy			
	2	4,455,142	06/19/1984	Martins et al.			
	3	5,487,897	01/30/1996	Polson et al.			
	4	5,564,312	08/05/1997	Andrulis, Jr. et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	5	0 308 210	03/22/1989	Europe				
	6	2 145 931	04/11/1985	Great Britain				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	7	Enk A.H. et al. 1993 "An essential role of Langerhans cell-derived IL-1 β in the initiation of primary immune response in skin," <i>J. Immunol.</i> 150:3698-3704.
	8	Supplemental European Search Report from corresponding application EP 98 91 8392, mailed on October 21, 2004.

O:\DOCS\WXG\WXG-6307.DOC111104

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	